SKI II

本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断

SKI II is a highly selective and non-ATP-competitive S1P receptor inhibitor (IC50: 0.5 μM) while exhibiting no inhibitory action on other kinases including PKCα, PI3K, and ERK2.

SKI-II is a selective non-lipid inhibitor of sphingosine kinase (IC50 = 0.5 μM). nhibits acute myelogenous leukemia cell growth in vitro and in vivo. SKI-II was more efficient than two known SphK1 inhibitors SK1-I and FTY720 in inhibiting AML cells. Meanwhile, it induced dramatic apoptosis in above AML cells, and the cytotoxicity by SKI-II was almost reversed by the general caspase inhibitor z-VAD-fmk. SKI-II treatment inhibited SphK1 activation, and concomitantly increased level of sphingosine-1-phosphate (S1P) precursor ceramide in AML cells.

SKI-II; SKI II. Sphingosine kinase inhibitor II

Others

Other Targets

SphK1

Cancer

——

312636-16-1

302.78

C15H11ClN2OS

98%

DMSO : ≥ 100 mg/mL; 330.27 mM

c1cc(ccc1c1csc(n1)Nc1ccc(cc1)O)Cl

4-[[4-(4-Chlorophenyl)-2-thiazolyl]amino]phenol

(-20℃)

With Ice Pack

≥ 2 years